Skip to main content
TipRanks
Go Ultimate75% OFF

Royalty Pharma (RPD) Stock Forecast & Price Target

6 Followers
See the Price Targets and Ratings of:

RPD Analyst Ratings

Strong Buy
6Ratings
6Buy0Hold0Sell
Based on 6 analysts giving stock ratings to Royalty Pharma in the past 3 months

RPD Stock 12 Month Forecast

€63.88▲(2.50% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Royalty Pharma in the last 3 months. The average price target is EUR 63.88 with a high forecast of EUR 70.51 and a low forecast of EUR 56.95. The average price target represents a 2.50% change from the last price of EUR 62.32.
Highest Price Target€70.51Average Price Target€63.88Lowest Price Target€56.95

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:RPD
Price TargetArticle
Citi€63.28→€70.51buy13.14%UpsideReiterated11/05/26
Morgan Stanley€60.56→€67.79buy8.78%UpsideAssigned11/05/26
J.P. Morgan€56.04→€66.89buy7.33%UpsideReiterated11/04/26
Bank of America Securities€56.95buy-8.62%DownsideReiterated10/09/26
UBS€59.66buy-4.27%DownsideAssigned09/08/26
TD Cowen€58.76→€61.47buy-1.37%DownsideAssigned09/08/26
Goldman Sachs€53.33→€59.66buy-4.27%DownsideReiterated08/06/26
Evercore ISI―hold―Reiterated02/12/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PLSEPulse Biosciences
SLDBSolid Biosciences
RZLTRezolute
IMUXImmunic
MDWDMediwound

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Royalty Pharma

3 Months
Success Rate19/25 ratings generated profit
76%
Average Return
+5.75%

Copying Geoff Meacham's trades and holding each position for 3 Months would result in 76.00% of your transactions generating a profit, with an average return of +5.75% per trade.

1 Year
Success Rate18/25 ratings generated profit
72%
Average Return
+22.10%

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 72.00% of your transactions generating a profit, with an average return of +22.10% per trade.

2 Years
Success Rate21/25 ratings generated profit
84%
Average Return
+51.73%

Copying Geoff Meacham's trades and holding each position for 2 Years would result in 84.00% of your transactions generating a profit, with an average return of +51.73% per trade.

RPD Analyst Recommendation Trends

05101520Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for RPD
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy00000
Buy108131311
Hold00000
Sell00000
Strong Sell00000
total108131311

In the current month, RPD has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RPD average Analyst price target in the past 3 months is 63.88.

RPD Financial Forecast

€0€0.5€1€1.5€2Q1 2026Q3 2026Q4 2026
High€1.47
Consensus€1.40
Low€1.33

RPD Earnings Forecast

Next quarter’s earnings estimate for RPD is EUR 1.40 with a range of EUR 1.33 to EUR 1.47. The previous quarter’s EPS was EUR 1.08. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€556.9M€638.6M€720.3M€802M€883.7MQ1 2026Q3 2026Q4 2026
High€884M
Consensus€860M
Low€819M

RPD Sales Forecast

Next quarter’s sales forecast for RPD is EUR 860.20M with a range of EUR 819.25M to EUR 883.69M. The previous quarter’s sales results were EUR 617.88M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

RPD Stock Forecast FAQ

What is DE:RPD’s average 12-month price target, according to analysts?
Based on analyst ratings, Royalty Pharma’s 12-month average price target is €63.88.
What is DE:RPD’s upside potential, based on the analysts’ average price target?
Royalty Pharma has 2.50% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Royalty Pharma a Buy, Sell or Hold?
Royalty Pharma has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Royalty Pharma’s share price target?
The average share price target for Royalty Pharma is €63.88. This is based on 6 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €70.51, and the lowest forecast is €56.95. The average share price target represents a 2.50% increase from the current price of €62.32.
What do analysts say about Royalty Pharma?
Royalty Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of Royalty Pharma?
To buy shares of DE:RPD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.